Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
NCT03377803 is registered in ClinicalTrials.gov with Verrica Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 14, 2018
- Completion date
- September 26, 2018
- Enrollment
- 262 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.